Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 44.5% in January

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 55,812 shares, a decrease of 44.5% from the December 31st total of 100,600 shares. Based on an average daily trading volume, of 1,063,819 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 1,063,819 shares, the days-to-cover ratio is currently 0.1 days.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $13.17 on Friday. The stock has a market capitalization of $52.85 billion, a P/E ratio of -146.32, a price-to-earnings-growth ratio of 4.83 and a beta of 0.66. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.98. The firm has a 50 day moving average of $10.91 and a 200-day moving average of $9.02.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Finally, JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.